AUTOLOGOUS PLATELET-RICH PLASMA IN THE TREATMENT OF PATIENTS WITH KNEE ARTHRITIS III STAGE

D. A. Malanin , V. V. Novochadov , S. Demkin , M. V. Demeshenko , D. I. Danilov

Traumatology and Orthopedics of Russia ›› 2014, Vol. 20 ›› Issue (3) : 52 -59.

PDF
Traumatology and Orthopedics of Russia ›› 2014, Vol. 20 ›› Issue (3) : 52 -59. DOI: 10.21823/2311-2905-2014-0-3-52-59
Clinical studies
other

AUTOLOGOUS PLATELET-RICH PLASMA IN THE TREATMENT OF PATIENTS WITH KNEE ARTHRITIS III STAGE

Author information +
History +
PDF

Abstract

The purpose of the study - to determine the effectiveness of using PRP in the treatment of patients with stage III knee arthritis. Material for the study - 81 patients , two clinical groups with unilateral ( 9 patients - 15%) or bilateral ( 51 patients - 85%) with stage III knee arthritis. The first group of patients in an amount of 40 people were treated by introducing into the knee joint of autologous platelet-rich plasma 1 every three weeks. In the comparison group of 41 patients were symptomatic treatment with non-steroidal anti-inflammatory drugs. Evaluation of the results was performed using the LEKEN scale, VAS, verbal evaluation of the effectiveness of pain at 3, 6, 9 weeks after the treatment. Results: satisfactory result has increased to 52.5 %±0.2% of patients in week 9 of the main group. Score VAS and LEKEN scale gives a clear picture to the marked reduction in pain 9 weeks to 4 observation points. Intraarticular injection of PRP in the treatment of patients with stage III can reduce the severity of pain, improve knee function and quality of life for 9 weeks during their preparation for surgical treatment. Adherence to treatment of patients with stage III receiving intraarticular PRP, close to 98%.

Cite this article

Download citation ▾
D. A. Malanin, V. V. Novochadov, S. Demkin, M. V. Demeshenko, D. I. Danilov. AUTOLOGOUS PLATELET-RICH PLASMA IN THE TREATMENT OF PATIENTS WITH KNEE ARTHRITIS III STAGE. Traumatology and Orthopedics of Russia, 2014, 20(3): 52-59 DOI:10.21823/2311-2905-2014-0-3-52-59

登录浏览全文

4963

注册一个新账户 忘记密码

References

[1]

Базарный В.В. Синовиальная жидкость клиникодиагностическое значение лабораторного анализа. Екатеринбург; 1999. 80 с.

[2]

Мастыков А.Н., Дейкало В.П., Самсонова И.В., Болобошко К.Б. Эффективность применения обогащенной тромбоцитами плазмы при лечении травматических дефектов хряща суставных поверхностей. Новости хирургии. 2013;(21):3-9.

[3]

Широкова Л. Ю., Носков С. М., Голикова Ю. В. Применение аутологичной обогащенной тромбоцитами плазмы при гонартрозе. Клиническая геронтология. 2012;(18):9-13.

[4]

Baltzer A.W., Moser C., Jansen S.A., Krauspe R. Autologous conditioned serum (Orthokine) is an effective treatment for knee osteoarthritis. Osteoarthr. Cartil. 2009; 17:152-160.

[5]

Berghoff W.J., Pietrzak W.S., Rhodes R.D. Platelet-rich plasma application during closure following total knee arthroplasty. Orthopedics. 2006; 29:590-598.

[6]

Cerza F., Carni S., Carcangiu A. Comparison between hyaluronic acid and platelet-rich plasma, intra articular infiltration in the treatment of gonarthrosis. Am. J. Sports Med. 2012; 40:2822-2827.

[7]

Crane D., Platelet Rich Plasma (PRP) Matrix Grafts. Practical PAIN MANAGEMENT. 2008; 8:12-26. Everts P., Knape J., Weibrich G., Schönberger J.,

[8]

Hoffmann J., Overdevest E., Box H., Zundert A. Plateletrich plasma and platelet gel: a Review. J. Extra Corpor. Technol. 2006; 38:174-187.

[9]

Filardo G., Kon E. Platelet-rich plasma intra-articular knee injections for the treatment of degenerative cartilage lesions and osteoarthritiset. Knee Surg. Sports Traumatol. Arthrosc. 2011; 19:528-535.

[10]

Foster T.E., Puskas B.L., Mandelbaum B.R. Platelet rich plasma: from basic science to clinical application. Am. J. Sports Med. 2009; 11:2259-2272.

[11]

Foster T.E., Puskas B.L., Mandelbaum B.R., Gerhardt M.B., Rodeo S.A. Platelet-rich plasma: from basic science to clinical applications. Am. J. Sports Med. 2009; 11:2259-2272.

[12]

Jüni P., Reichenbach S., Trelle S. et al. Efficacy and safety of intraarticular hylan or hyaluronic acids for osteoarthritis of the knee. Arthr. Rheum. 2007; 11:3610-3619.

[13]

Khoshbin A., Leroux T., Wasserstein D. et al. The efficacy of platelet-rich plasma in the treatment of symptomatic knee osteoarthritis: a systematic review with quantitative synthesis. Arthroscopy. 2013; 12:2037-2048.

[14]

Kon E., Mandelbaum B., Buda R. Platelet-rich plasma intra-articular injection versus hyaluronic acid viscosupplementation as treatments for cartilage pathology: from early degeneration to osteoarthritis. Arthroscopy. 2011; 27:1490-1501.

[15]

Loke Y.K. et al. Meta-analysis: gastrointestinal bleeding due to interaction between selective serotonin uptake inhibitors and non-steroidal anti-inflammatory drugs. Aliment. Pharmacol. Ther. 2006; 27:31-40.

[16]

Nam J.L., Winthrop K.L., Van Vollenhoven et al. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann. Rheum. Dis. 2010; 69:976-986.

[17]

Patel S., Dhillon M.S., Aggarwal S., Marwaha N., Jain A. Treatment with platelet-rich plasma is more effective than placebo for knee osteoarthritis: а prospective, double-blind, randomized trial. Am. J. Sports Med. 2013; 41:356-364.

[18]

Weibrich G., Hansen T., Kleis W., Buch R., Hitzler W.E. Effect of platelet concentration in plateletrich plasma on peri-implant bone regeneration. Bone. 2004; 34:665-671.

AI Summary AI Mindmap
PDF

132

Accesses

0

Citation

Detail

Sections
Recommended

AI思维导图

/